Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a research report issued on Wednesday. They currently have a $91.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $104.00. Stifel Nicolaus’ price objective indicates a potential upside of 29.32% from the stock’s previous close.

Several other equities analysts also recently issued reports on the stock. SunTrust Banks, Inc. reissued a “buy” rating and set a $82.00 price target (down from $95.00) on shares of Sage Therapeutics in a report on Wednesday. Canaccord Genuity cut their price target on shares of Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a report on Tuesday. J P Morgan Chase & Co cut their price target on shares of Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a report on Tuesday. Cowen and Company dropped their target price on shares of Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, BidaskClub downgraded shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $84.08.

Sage Therapeutics (NASDAQ:SAGE) opened at 70.37 on Wednesday. The stock has a 50 day moving average of $82.79 and a 200 day moving average of $74.97. The company’s market capitalization is $2.63 billion. Sage Therapeutics has a 12-month low of $38.30 and a 12-month high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.25). During the same quarter in the previous year, the company earned ($1.08) EPS. On average, equities research analysts predict that Sage Therapeutics will post ($7.38) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Sage Therapeutics’ (SAGE) Buy Rating Reiterated at Stifel Nicolaus” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/13/sage-therapeutics-inc-sage-rating-reiterated-by-stifel-nicolaus.html.

Several institutional investors and hedge funds have recently bought and sold shares of SAGE. Dynamic Technology Lab Private Ltd grew its holdings in Sage Therapeutics by 164.4% during the second quarter. Dynamic Technology Lab Private Ltd now owns 7,513 shares of the biopharmaceutical company’s stock valued at $598,000 after purchasing an additional 4,671 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Sage Therapeutics by 19.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,034 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 497 shares during the period. California State Teachers Retirement System grew its holdings in Sage Therapeutics by 3.2% during the second quarter. California State Teachers Retirement System now owns 61,252 shares of the biopharmaceutical company’s stock valued at $4,878,000 after purchasing an additional 1,910 shares during the period. Raymond James Financial Services Advisors Inc. grew its holdings in Sage Therapeutics by 41.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 8,682 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 2,525 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Sage Therapeutics by 13.5% during the second quarter. The Manufacturers Life Insurance Company now owns 26,980 shares of the biopharmaceutical company’s stock valued at $2,149,000 after purchasing an additional 3,216 shares during the period.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.